The Mayo Clinic Cancer Center (MCCC) is a matrix center within the Mayo Clinic/ Mayo Medical School. The Center is made up of 351 members from 87 departments and divisions based at 3 geographical sites (Rochester, MN-MCR;Jacksonville, FL-MCF;and Phoenix/ Scottsdale, AZ-MCA). Our mission is to promote and facilitate research on the incidence, etiology, and molecular basis of cancer, and then through education and direct application of the results of such research, translate the discoveries into improved methods for cancer prevention, detection, diagnosis, prognosis, and therapy. MCCC, like Mayo Clinic in general, serves not only patients in the immediate geographical areas of MCR, MCF, and MCA, but also patients from throughout the USA and the rest of the world. MCCC has 10 research programs: Cell Biology;Developmental Therapeutics;Cancer Immunology and Immunotherapy;Gene and Virus Therapy;Women's Cancer;Gastrointestinal Cancer;Hematologic Malignancies;Neuro-oncology;Genetic Epidemiology and Risk Assessment;and Cancer Prevention and Control. Research is facilitated by: 1) 13 shared resources: Survey Research, Pharmacy, Biostatistics, Bioinformatics, Biospecimens Accessioning and Processing, Pathology Research Core, Transgenic and Knockout Core, Proteomics, Microscopy and Cell Analysis, Pharmacology, Gene and Virus Therapy, Cytogenetics, and Gene Analysis;and 2) clinical support management activities including Clinical Trials Office, PRMS, and Data and Safety Monitoring. Since the last renewal, MCCC has grown with an increase in overall peer-reviewed funding from $105.9 million to $123.6 million and an increase in NCI funding from $75.7 million to $92.7M. Of particular note is a new Ovarian SPORE and a new training grant. Furthermore, there has been successful competitive renewal of 4 other SPOREs (Lymphoma, Brain, Breast, Pancreas), as well as several multi-disciplinary and training grants. Research productivity and excellence is demonstrated by high-impact clinical and scientific publications -- several of which have led to changes in cancer care. As the MCCC moves forward, a major cross-programmatic effort will be to build on research started during the past grant period in the cancer genome with the development of new genome-guided therapy approaches.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Basch, Ethan; Rogak, Lauren J; Dueck, Amylou C (2016) Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials. Clin Ther 38:821-30
Renner, Danielle N; Malo, Courtney S; Jin, Fang et al. (2016) Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model. Neurotherapeutics 13:226-36
Navari, Rudolph M; Qin, Rui; Ruddy, Kathryn J et al. (2016) Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med 375:134-42
Amirian, E Susan; Zhou, Renke; Wrensch, Margaret R et al. (2016) Approaching a Scientific Consensus on the Association between Allergies and Glioma Risk: A Report from the Glioma International Case-Control Study. Cancer Epidemiol Biomarkers Prev 25:282-90
Cuellar-Partida, Gabriel; Lu, Yi; Dixon, Suzanne C et al. (2016) Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Hum Genet 135:741-56
Ye, Zi; Austin, Erin; Schaid, Daniel J et al. (2016) A multi-locus genetic risk score for abdominal aortic aneurysm. Atherosclerosis 246:274-9
McCormack, Valerie A; Burton, Anya; dos-Santos-Silva, Isabel et al. (2016) International Consortium on Mammographic Density: Methodology and population diversity captured across 22 countries. Cancer Epidemiol 40:141-51
Basal, E; Ayeni, T; Zhang, Q et al. (2016) Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer. Curr Mol Med 16:222-31
Vaidhyanathan, Shruthi; Wilken-Resman, Brynna; Ma, Daniel J et al. (2016) Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases. J Pharmacol Exp Ther 356:251-9
Yoon, H H; Foster, N R; Meyers, J P et al. (2016) Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance). Ann Oncol 27:339-44

Showing the most recent 10 out of 948 publications